Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» FDA
FDA
FDA approves Ardelyx's kidney disease-related drug
Reuters
Tue, 10/17/23 - 09:59 pm
Ardelyx
chronic kidney disease
FDA
Xphozah
FDA Warning Letter to J&J's Abiomed Has Broad Implications for Medtech
Medical Devices and Diagnostics Industry
Tue, 10/17/23 - 10:20 am
Medtech
JNJ
FDA
warning letters
Aldeyra Anticipates FDA Rejection of Dry Eye Drug Following Regulatory Meeting
BioSpace
Tue, 10/17/23 - 10:17 am
Aldeyra Therapeutics
dry eye disease
reproxalap
FDA
Masimo wins de novo authorization for measure of high blood oxygen levels
Medtech Dive
Mon, 10/16/23 - 11:32 pm
Masimo
Medtech
pulse oximetry
FDA
ORi
Bristol Myers Squibb's Opdivo reign expands with new earlier-stage melanoma nod
Fierce Pharma
Mon, 10/16/23 - 11:45 am
Bristol Myers Squibb
Opdivo
melanoma
FDA
AZ’s Tagrisso plus chemo get fast FDA review for lung cancer
Pharmaphorum
Mon, 10/16/23 - 10:20 am
AstraZeneca
FDA
Tagrisso
non-small cell lung cancer
EGFR-positive non-small cell lung cancer
Potential FDA approval for Supernus’s SPN-830 in Parkinson’s but challenges remain
Clinical Trials Arena
Mon, 10/16/23 - 10:18 am
Supernus
SPN-830
Parkinson's Disease
FDA
Pfizer takes aim at BMS' first-in-class Zeposia with FDA nod for ulcerative colitis drug Velsipity
Fierce Pharma
Fri, 10/13/23 - 10:35 am
Bristol Myers Squibb
Zeposia
Pfizer
Velsipity
etrasimod
ulcerative colitis
FDA
Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future
Pharma Voice
Thu, 10/12/23 - 05:32 pm
Alnylam
Pharma CEOs
Yvonne Greenstreet
FDA
Onpattro
Lilly’s Mirikizumab Shows Long-Term Remission in Phase III Crohn’s Trial
BioSpace
Thu, 10/12/23 - 05:22 pm
Eli Lilly
mirikizumab
Crohn's Disease
FDA
PepGen cleared by FDA to begin study of muscular dystrophy drug
BioPharma Dive
Thu, 10/12/23 - 05:20 pm
PepGen
FDA
myotonic muscular dystrophy
FDA finds no misconduct at trial sites for Pfizer's Lyme disease shot, Care Access says
Reuters
Thu, 10/12/23 - 11:36 am
Pfizer
clinical trials
Lyme disease
Valneva
vaccines
FDA
Pfizer, playing catch-up with Novartis, bags FDA approval for drug combo in lung cancer
Fierce Pharma
Thu, 10/12/23 - 11:34 am
Pfizer
Braftovi
Maktovi
metastatic non-small cell lung cancer
FDA
FDA Rejects Alvotech’s Stelara Biosimilar as Manufacturing Problems Continue
BioSpace
Thu, 10/12/23 - 10:22 am
Alvotech
AVT04
JNJ
Stelara
biosimilars
FDA
FDA clears Kyverna’s IND for scleroderma therapy
Pharmaceutical Business Review
Thu, 10/12/23 - 10:06 am
Kyverna Therapeutics
KYV-101
scleroderma
FDA
FDA Decision On Interchangeable Exclusivity Allows Pfizer To Rival Boehringer On Adalimumab
Generics Bulletin
Mon, 10/9/23 - 11:35 pm
Pfizer
Humira
biosimilars
adalimumab
AbbVie
interchangeability
FDA
FDA denies expanded approval for Alnylam RNA drug
BioPharma Dive
Mon, 10/9/23 - 10:15 am
Alnylam
FDA
RNA
Patisiran
ATTR amyloidosis
Novartis Wins FDA Approval for Intravenous Cosentyx Formulation
BioSpace
Mon, 10/9/23 - 10:14 am
Novartis
Cosentyx
FDA
ankylosing spondylitis
psoriatic arthritis
non-radiographic axial spondyloarthritis
Amgen's Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Fierce Pharma
Thu, 10/5/23 - 09:13 pm
Amgen
Lumakras
FDA
KRAS inhibitors
FDA expert panel endorses idea of removing a component from flu vaccine
Stat
Thu, 10/5/23 - 09:05 pm
FDA
vaccines
flu vaccines
Pages
« first
‹ previous
…
9
10
11
12
13
14
15
16
17
…
next ›
last »